Haploidentical stem cell transplant with two post-transplant medicines
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a way to treat certain blood cancers using a stem cell transplant from a partially matched (haploidentical) donor. It aims to make the transplant safer and reduce the chance of the immune reaction that can follow transplant, using post-transplant cyclophosphamide and bortezomib.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You need a stem cell transplant for a blood cancer, and you do NOT have a fully matched donor option, but you may have a partially matched (haploidentical) related donor.
- A doctor says you can tolerate transplant based on heart and lung function (heart pumping strength above 40% and lung test above 45%).
- Blood and organ tests fit the trial limits, including bilirubin up to 1.5 and liver enzymes up to 200 (AST/ALT), and kidney function with clearance at least 60.
- Your donor can provide stem cells using a peripheral blood collection (not just other donor sources).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to do a stem cell transplant for people with hard-to-treat blood cancers. It combines a half-matched family donor (haploidentical) with a cord blood unit to help the transplant work better.
This trial tests a stem cell transplant from a family donor whose tissue type is only partly matched, for adults with blood cancers who don't have a fully matched sibling or other closely matched donor. The goal is to make transplant possible for more patients.
This trial tests a transplant using stem cells from an unrelated donor who is not a perfect match for your tissue type. It may be an option for people with blood cancers who can't find a fully matched related donor and need a transplant quickly.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
This study is a registry that tracks outcomes for adults with blood diseases (such as leukemia, lymphoma, or severe aplastic anemia) who receive a haploidentical stem cell transplant—a transplant from a half-matched donor. The goal is to gather real-world data to understand how well this approach works for people who do not have a fully matched donor.
Hear when a new Hematological Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.